SAB Biotherapeutics (SABS) Preferred Stock Liabilities (2021)
Historic Preferred Stock Liabilities for SAB Biotherapeutics (SABS) over the last 1 years, with Q3 2021 value amounting to $116.2 million.
Historic Preferred Stock Liabilities for SAB Biotherapeutics (SABS) over the last 1 years, with Q3 2021 value amounting to $116.2 million.
| Date | Value |
|---|---|
Offer Ends In
Starting from $49 $19 / month